Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Phase 2, Open Label, Ascending Dose Study to Evaluate the Safety and Efficacy of RVP-001 and to Identify an Appropriate Dose to Detect CNS Lesions in Adult Patients

NCT06322342 is registered in ClinicalTrials.gov with Reveal Pharmaceuticals Inc. as lead sponsor.

NCT NCT06322342
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06322342 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Phase 2, Open Label, Ascending Dose Study to Evaluate the Safety and Efficacy of RVP-001 and to Identify an Appropriate Dose to Detect CNS Lesions in Adult Patients
Lead sponsor
Reveal Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 15, 2024
Completion date
December 19, 2025
Enrollment
18 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acoustic neuroma, brain cancer, brain metastases, brain neoplasm, primary, brain neoplasms, brain neoplasms, benign, brain tumor, brain tumor, primary, brain tumor, recurrent, brain tumors, central nervous system (cns) lesions, cns cancer, cns lesion, cns lymphoma, cns metastases, cns tumor, glioma, meningioma, multiple sclerosis, multiple sclerosis brain lesion, neoplasia, neurofibroma, neuroinflammation, schwannomas, von hippel lindau